The city of Clearwater, Florida, currently has 7 active clinical trials seeking participants for Arthritis research studies.
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Clinical Research of West Florida, Clearwater, Florida
Conditions: Arthritis, Psoriatic
Study of GS-0272 in Participants With Rheumatoid Arthritis
Recruiting
The goals of this clinical study are to learn more about the study drug, GS-0272, and its safety and tolerability following multiple doses in participants with rheumatoid arthritis (RA). The primary objectives of this study are to assess the safety and tolerability of multiple ascending doses of GS-0272 and to characterize the pharmacokinetics of GS-0272 following multiple doses of GS-0272, in participants with RA.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2024
Locations: Clinical Research of West Florida, Inc., Clearwater, Florida
Conditions: Rheumatoid Arthritis
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
Recruiting
An open label phase 3 study
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Sunpharma site no. 21, Clearwater, Florida
Conditions: Psoriatic Arthritis
RA-PRO PRAGMATIC TRIAL
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: American Arthritis and Rheumatology Associates LLC, Clearwater, Florida
Conditions: Rheumatoid Arthritis
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients
Recruiting
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/31/2024
Locations: Arthrosi Investigative Site (149), Clearwater, Florida
Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
Recruiting
This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Sunpharma site no. 21, Clearwater, Florida
Conditions: Active Psoriatic Arthritis
The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis
Recruiting
The goal of treating patients diagnosed with rheumatoid arthritis (RA) is to achieve remission or low disease activity and thereby prevent joint damage, loss of physical function, and disability. Optimal management requires regular assessment of disease activity, with treatment changes made as needed for optimal efficacy. Vectra is a blood serum test that looks at 12 biomarkers and produces a score on a scale of 1 to 100. The Vectra score has been shown to be the strongest predictor of risk for... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: Robert W. Levin, MD, PA, Clearwater, Florida
Conditions: Rheumatoid Arthritis (RA)